Neuroendocrine tumors: A critical appraisal of management strategies

Pancreas

Volumn 39, Issue 6, 2010, Pages 801-818

  Vinik, Aaron I ^a   Anthony, Lowell ^b   Boudreaux, J Philip ^a,c   Go, Vay Liang W ^d   O'Dorisio, Thomas M ^e   Ruszniewski, Philippe ^f   Woltering, Eugene A ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c Department of Surgery Ochsner Kenner ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f BEAUJON HOSPITAL   (France)

Author keywords

neuroendocrine tumors; overall survival; progression free survival; somatostatin analogs; tumor proliferation

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CELL PROLIFERATION; CHEMOEMBOLIZATION; CLINICAL PRACTICE; CYTOREDUCTIVE SURGERY; HUMAN; MEDICAL EDUCATION; MEDICAL SOCIETY; MEDLINE; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; SCIENTIFIC LITERATURE; SURVIVAL RATE; SURVIVAL TIME; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; NEUROENDOCRINE TUMORS; OCTREOTIDE; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 77955207094     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181ea5839     Document Type: Article

References (89)

1. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28): 4656Y4663.
2. van der Lely AJ, de Herder WW. Carcinoid syndrome: diagnosis and medical management. Arq Bras Endocrinol Metabol. 2005;49(5): 850Y860.
3. Modlin IM, Kidd M, Latich I, et al. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128(6):1717Y1751.
4. Warner RR. Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology. 2005;128(6): 1668Y1684.
5. Hodul P, Malafa M, Choi J, et al. The role of cytoreductive hepatic surgery as an adjunct to the management of metastatic neuroendocrine carcinomas. Cancer Control. 2006;13(1):61Y71.
6. Lal A, Chen H. Treatment of advanced carcinoid tumors. Curr Opin Oncol. 2006;18(1):9Y15.
7. Sartori P, Mussi C, Angelini C, et al. Palliative management strategies of advanced gastrointestinal carcinoid neoplasms. Langenbecks Arch Surg. 2005;390(5):391Y396.
8. Hellman P, Lundstrom T, Ohrvall U, et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg. 2002;26(8):991Y997.
9. Givi B, Pommier SJ, Thompson AK, et al. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery. 2006;140(6):891Y897.
10. Modlin IM, Oberg K, eds. A Century of Advances in Neuroendocrine Tumor Biology and Treatment. Hannover, Germany: Felsenstein CCCP; 2007.
11. Pawlikowski M, Melen-Mucha G. Somatostatin analogsVfrom new molecules to new applications. Curr Opin Pharmacol. 2004;4(6):608Y613.
12. Ezzat S, Snyder PJ, Young WF, et al. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med. 1992;117(9):711Y718.
13. del Pozo E, Neufeld M, Schluter K, et al. Endocrine profile of a long-acting somatostatin derivative SMS 201-995. Study in normal volunteers following subcutaneous administration. Acta Endocrinol (Copenh). 1986;111(4):433Y439.
14. Grass P, Marbach P, Bruns C, et al. Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships. Metabolism. 1996;45 (8 suppl 1):27Y30.
15. Nicholls J, Wynick D, Domin J, et al. Pharmacokinetics of the long-acting somatostatin analogue octreotide (SMS 201-995) in acromegaly. Clin Endocrinol (Oxf). 1990;32(5):545Y550.
16. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17(2):600Y606.
17. Attanasio R, Baldelli R, Pivonello R, et al. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab. 2003;88(11):5258Y5265.
18. Caron P, Cogne M, Gusthiot-Joudet B, et al. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). Eur J Endocrinol. 1995;132(3):320Y325.
19. Kuhn JM, Legrand A, Ruiz JM, et al. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br J Clin Pharmacol. 1994;38(3):213Y219.
20. van Thiel SW, Romijn JA, Biermasz NR, et al. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol. 2004;150(4):489Y495.
21. Oberg K, Ferone D, Kaltsas G, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biotherapy. Neuroendocrinology. 2009;90(2):209Y213.
22. Ahlman H, Nilsson O, McNicol AM, et al. Poorly-differentiated endocrine carcinomas of midgut and hindgut origin. Neuroendocrinology. 2008;87(1):40Y46.
23. Rindi G, de Herder WW, O'Toole D, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors: why such guidelines and how we went about It. Neuroendocrinology. 2006;84(3):155Y157.
24. Woltering EA, Mamikunian PM, Zietz S, et al. Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors. Pancreas. 2005;31(4):392Y400.
25. Woltering EA, Salvo VA, O'Dorisio TM, et al. Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients. Pancreas. 2008;37(1):94Y100.
26. Schran HF, Hager DF. Comments on BClinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients[. Pancreas. 2008;37(3): 334Y335; author reply 336Y337.
27. Joseph S, Li G, Lindholm E, et al. A prospective trial on the effect of body mass index and sex on plasma octreotide levels in patients undergoing long-term octreotide LAR therapy. Pancreas. 2010.
28. Vinik AI, Silva MP, Woltering G, et al. Biochemical testing for neuroendocrine tumors. Pancreas. 2009;38(8):876Y889.
29. Modlin IM, Pavel M, Kidd M, et al. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010;31(2):169Y188.
30. Ruszniewski P, Ish-Shalom S, Wymenga M, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology. 2004;80(4):244Y251.
31. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15(6):966Y973.
32. Gustafsson BI, Hauso O, Drozdov I, et al. Carcinoid heart disease. Int J Cardiol. 2008;129(3):318Y324.
33. Moller JE, Connolly HM, Rubin J, et al. Factors associated with progression of carcinoid heart disease. N Engl J Med. 2003;348(11):1005Y1015.
34. Grozinsky-Glasberg S, Grossman AB, Korbonits M. The role of somatostatin analogues in the treatment of neuroendocrine tumours. Mol Cell Endocrinol. 2008;286(1Y2):238Y250.
35. Grozinsky-Glasberg S, Shimon I, Korbonits M, et al. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer. 2008;15(3):701Y720.
36. Ducreux M, Ruszniewski P, Chayvialle JA, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol. 2000;95(11):3276Y3281.
37. Verslype C, Carton S, Borbath I, et al. The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours. Acta Gastroenterol Belg. 2009; 72(1):54Y58.
38. Bajetta E, Procopio G, Catena L, et al. Lanreotide Autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a phase III Study. Cancer. 2006;107(10):2474Y2481.
39. Welin SV, Janson ET, Sundin A, et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol. 2004;151(1):107Y112.
40. Oberg KE. Is it time to widen the use of somatostatin analogs in neuroendocrine tumors? J Clin Oncol. 2009;27(28):4635Y4636.
41. Chua YJ, Michael M, Zalcberg JR, et al. Antitumor effect of somatostatin analogs in neuroendocrine tumors. J Clin Oncol. 2010;28(3):e41Ye42; author reply e43Ye44.
42. Campana D, Nori F, Pezzilli R, et al. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer. 2008;15(1):337Y342.
43. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 2006;17(12):1733Y1742.
44. Vinik AI, Tsai ST, Moattari AR, et al. Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes. Am J Med. 1986;81(6B):23Y40.
45. Prevost G, Foehrle E, Thomas F, et al. Growth of human breast cancer cell lines is inhibited by the somatostatin analog BIM23014. Endocrinology. 1991;129(1):323Y329.
46. Weckbecker G, Raulf F, Stolz B, et al. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther. 1993; 60(2):245Y264.
47. Weckbecker G, Tolcsvai L, Stolz B, et al. Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(alpha)anthracene-induced rat mammary carcinomas. Cancer Res. 1994;54(24):6334Y6337.
48. Woltering EA, Barrie R, O'Dorisio TM, et al. Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res. 1991;50(3):245Y251.
49. Woltering EA, Watson JC, Alperin-Lea RC, et al. Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs. 1997;15(1):77Y86.
50. Barrie R,Woltering EA, Hajarizadeh H, et al. Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J Surg Res. 1993;55(4):446Y450.
51. Patel PC, Barrie R, Hill N, et al. Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis. Surgery. 1994;116(6):1148Y1152.
52. Danesi R, Agen C, Benelli U, et al. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin Cancer Res. 1997;3(2):265Y272.
53. Danesi R, Del Tacca M. The effects of the somatostatin analog octreotide on angiogenesis in vitro. Metabolism. 1996; 45(8 suppl 1):49Y50.
54. Woltering EA, Lewis JM, Maxwell PJT, et al. Development of a novel in vitro human tissue-based angiogenesis assay to evaluate the effect of antiangiogenic drugs. Ann Surg. 2003;237(6):790Y798; discussion 798Y800.
55. Watson JC, Balster DA, Gebhardt BM, et al. Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br J Cancer. 2001;85(2):266Y272.
56. Woltering EA. Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives. Cancer Biother Radiopharm. 2003;18(4):601Y609.
57. Luo Q, Peyman GA, Conway MD, et al. Effect of a somatostatin analog (octreotide acetate) on the growth of retinal pigment epithelial cells in culture. Curr Eye Res. 1996;15(9):909Y913.
58. Gargiulo P, Giusti C, Pietrobono D, et al. Diabetes mellitus and retinopathy. Dig Liver Dis. 2004;36(suppl 1):S101YS105.
59. Higgins RD, Yan Y, Schrier BK. Somatostatin analogs inhibit neonatal retinal neovascularization. Exp Eye Res. 2002;74(5):553Y559.
60. Anthony L, Johnson D, Hande K, et al. Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol. 1993;32(2):217Y223.
61. Hejna M, Schmidinger M, Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol. 2002;13(5):653Y668.
62. Kvols LK, Woltering EA. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. Anticancer Drugs. 2006;17(6):601Y608.
63. Melmed S. Medical progress: acromegaly. N Engl J Med. 2006;355(24):2558Y2573.
64. Vinik A, Moattari AR. Use of somatostatin analog in management of carcinoid syndrome. Dig Dis Sci. 1989;34(suppl 3):14SY27S.
65. Fjallskog ML, Ludvigsen E, Stridsberg M, et al. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol. 2003;20(1):59Y67.
66. Anthony CT, Hughey S, Lyons J, et al. The effect of drug dose and drug exposure time on the binding, internalization, and cytotoxicity of radiolabeled somatostatin analogs. J Surg Res. 2004;119(1):1Y13.
67. Reubi JC, Waser B, Cescato R, et al. Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients. J Clin Endocrinol Metab. 2010;95(5):2343Y2350.
68. Buscail L, Delesque N, Esteve JP, et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci U S A. 1994;91(6):2315Y2319.
69. Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med. 1998;217(2): 143Y152.
70. Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev. 1991;12(4):450Y482.
71. Bousquet C, Puente E, Buscail L, et al. Antiproliferative effect of somatostatin and analogs. Chemotherapy. 2001;47(suppl 2):30Y39.
72. Tesei A, Ricotti L, De Paola F, et al. Lanreotide-induced modulation of 5-fluorouracil or mitomycin C cytotoxicity in human colon cancer cell lines: a preclinical study. J Chemother. 2000;12(5):421Y430.
73. Lamberts SW, van Koetsveld P, Hofland LJ. The interrelationship between the anti-mitotic action of the somatostatin analog octreotide and that of cytostatic drugs and suramin. Int J Cancer. 1991;48(6): 938Y941.
74. Massari D, Trobonjac Z, Rukavina D, et al. SMS 201-995 enhances S-phase block induced by 5-fluorouracil in a human colorectal cancer cell line. Anticancer Drugs. 2005;16(9):989Y996.
75. Lee JM, Erlich RB, Bruckner HW, et al. A somatostatin analogue (SMS 201-995) alters the toxicity of 5-fluorouracil in Swiss mice. Anticancer Res. 1993;13(5A):1453Y1456.
76. Moreno A, Akcakanat A, Munsell MF, et al. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer. 2008;15(1): 257Y266.
77. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28(1):69Y76.
78. Schally AV, Srkalovic G, Szende B, et al. Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies. J Steroid Biochem Mol Biol. 1990;37(6):1061Y1067.
79. Niccoli P, Raoul J, Bang Y, et al. Updated safety and efficacy results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET). J Clin Oncol. 2010;28(suppl):7s.
80. Vinik A, Bang Y, Raoul J, et al. Patient-reported outcomes (PROs) in patients (pts) with pancreatic neuroendocrine tumors (NET) receiving sunitinib (SU) in a phase III trial. J Clin Oncol. 2010;28(suppl):7s.
81. Ricci S, Antonuzzo A, Galli L, et al. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol. 2000;11(9):1127Y1130.
82. Kolby L, Persson G, Franzen S, et al. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg. 2003;90(6):687Y693.
83. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer. 2006;95(9):1148Y1154.
84. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26(20):3403Y3410.
85. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23(12):2754Y2762.
86. van Essen M, Krenning EP, Bakker WH, et al. Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging. 2007;34(8):1219Y1227.
87. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124Y2130.
88. Ansell SM, Pitot HC, Burch PA, et al. A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer. 2001;91(8):1543Y1548.
89. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007;13(10):2986Y2991.